Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

Mutant RAS has remained recalcitrant to targeted therapy efforts. Here we demonstrate that combined treatment with poly ADP ribose polymerase (PARP) inhibitors and MEK inhibitors evokes unanticipated, synergistic cytotoxic effects in vitro and in vivo in multiple RAS mutant tumor models across tumor...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Transl Med
Päätekijät: Sun, Chaoyang, Fang, Yong, Yin, Jun, Chen, Jian, Ju, Zhenlin, Zhang, Dong, Chen, Xiaohua, Vellano, Christopher P., Jeong, Kang Jin, Ng, Patrick Kwok-Shing, Eterovic, A. Karina, Bhola, Neil H., Lu, Yiling, Westin, Shannon N, Grandis, Jennifer R., Lin, Shiaw-Yih, Scott, Kenneth L., Peng, Guang, Brugge, Joan, Mills, Gordon B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5919217/
https://ncbi.nlm.nih.gov/pubmed/28566428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal5148
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia